Synlogic Reports Fourth Quarter and Full Year 2022 : compare

– Phenylketonuria (PKU) program on track for Phase 3 trial initiation in first half of 2023 – – Rare Pediatric Disease Designation granted for SYNB1934...

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , Aoife Brennan , Society For Inherited Metabolic Disorders , Drug Administration , Synlogic Inc , Nasdaq , European Medicines Agency , Exchange Commission , Dave Hava As Head Of Research , Rare Pediatric Disease Designation , Synthetic Biotic , Synlogic President , Chief Executive , Recent Highlights , Inherited Metabolic Disorders , Dave Hava , Chief Scientific Officer , Synthetic Biotics , Ginkgo Bioworks , Private Securities Litigation Reform Act , Consolidated Statements , Nasdaq Sybx , Synlogic , Nc , Quarterly Earnings , Quarterly Results , Synbio , Synthetic Biology , Phenylketonuria , Omocystinuria , Oku , Fda , Ma , Icu ,